"Crowdsourcing digital health measures to predict Parkinson's disease ..."

Solveig K. Sieberts et al. (2021)

> Home

Details and statistics

DOI: 10.1038/S41746-021-00414-7

access: closed

type: Journal Article

metadata version: 2023-12-27

- view
  - electronic edition via DOI
  - unpaywalled version
  authority control:
- export record
  dblp key:
  - journals/npjdm/SiebertsSDPSSDP21
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/npjdm/SiebertsSDPSSDP21
Solveig K. Sieberts, Jennifer Schaff, Marlena Duda, Bálint Á Pataki, Ming Sun, Phil Snyder, Jean-Francois Daneault, Federico Parisi, Gianluca Costante, Udi Rubin, Peter Banda, Yooree Chae, Elias Chaibub Neto, Earl Ray Dorsey, Zafer Aydin, Aipeng Chen, Laura L. Elo, Carlos Espino, Enrico Glaab, Ethan Goan, Fatemeh Noushin Golabchi, Yasin Görmez, Maria K. Jaakkola, Jitendra Jonnagaddala, Riku Klén, Dongmei Li, Christian McDaniel, Dimitri Perrin, Thanneer M. Perumal, Nastaran Mohammadian Rad, Erin Rainaldi, Stefano Sapienza, Patrick Schwab, Nikolai Shokhirev, Mikko S. Venäläinen, Gloria Vergara-Diaz, Yuqian Zhang, Avner G. S. Abrami, Aditya Adhikary, Carla Agurto, Sherry Bhalla, Halil Ibrahim Bilgin, Vittorio Caggiano, Jun Cheng, Eden Deng, Qiwei Gan, Rajan Girsa, Zhi Han, Stephen Heisig, Kun Huang, Samad Jahandideh, Wolfgang Kopp, Christoph F. Kurz, Gregor Lichtner, Raquel Norel, G. P. S. Raghava, Tavpritesh Sethi, Nicholas Shawen, Vaibhav Tripathi, Matthew Tsai, Tongxin Wang, Yi Wu, Jie Zhang, Xinyu Zhang, Yuanjia Wang, Yuanfang Guan, Daniela Brunner, Paolo Bonato, Lara M. Mangravite, Larsson Omberg:
Crowdsourcing digital health measures to predict Parkinson's disease severity: the Parkinson's Disease Digital Biomarker DREAM Challenge. npj Digit. Medicine 4 (2021)

manage site settings

To protect your privacy, all features that rely on external API calls from your browser are turned off by default. You need to opt-in for them to become active. All settings here will be stored as cookies with your web browser. For more information see our F.A.Q.